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Abstract 37	
 38	
Cronobacter sakazakii is the most frequently clinically isolated species of the 39	
Cronobacter genus. However the virulence factors of C. sakazakii including their 40	
ability to overcome host barriers remains poorly studied. In this study, ten clinical 41	
isolates of C. sakazakii were assessed for their ability to invade and translocate 42	
through human colonic carcinoma epithelial cells (Caco-2) and human brain 43	
microvascular endothelial cells (HBMEC). Their ability to avoid phagocytosis in 44	
human macrophages U937 and human brain microglial cells was investigated. 45	
Additionally, they were tested for serum sensitivity and the presence of the 46	
Cronobacter plasminogen activation gene (cpa) gene, which is reported to confer 47	
serum resistance.  48	
 49	
Our data showed that the clinical C. sakazakii strains invaded and translocated 50	
through Caco-2 and HBMEC cell lines and some strains showed significantly higher 51	
levels of invasion and translocation. Moreover, C. sakazakii was able to persist and 52	
even multiply in phagocytic macrophage and microglial cells. All strains, except one, 53	
were able to withstand human serum exposure, the single serum sensitive strain was 54	
also the only one which did not encode for the cpa gene. These results demonstrate 55	
that C. sakazakii clinical isolates are able to overcome host barriers and evade the 56	
host immune response indicating their capacity to cause diseases such as 57	
necrotizing enterocolitis (NEC) and meningitis. Our data showed for the first time the 58	
ability of C. sakazakii clinical isolates to survive and multiply within human microglial 59	
cells. Additionally, it was shown that C. sakazakii clinical strains have the capacity to 60	
translocate through the Caco-2 and HBMEC cell lines paracellularly. 61	
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1. Introduction 73	
 74	
The Cronobacter genus is a member of the Enterobacteriaceae family. It comprises a 75	
distinct group of Gram-negative bacilli that are catalase-positive, oxidase-negative, 76	
non-spore forming, facultatively anaerobic, and motile via peritrichous flagella [1-3]. 77	
The Cronobacter genus contains 7 different species including C. condimenti, C. 78	
dublinensis, C. malonaticus, C. muytjensii, C. sakazakii, C. turicensis, and C. 79	
universalis [4-6]. C. sakazakii isolates represent 72.1% (n=1400) of the total 80	
Cronobacter genus isolates in the open access Cronobacter PubMLST database 81	
(http://www.pubmlst.org/cronobacter/), and this species has been  linked to several  82	
fatal NEC and meningitis cases around the world [7-10]. C. sakazakii have been 83	
isolated from prepared infant feeds associated with neonatal intensive care unit 84	
(NICU) infections. Cases of necrotising enterocolitis (NEC), bacteraemia, and 85	
meningitis have a 40-80% mortality rate, and 20% of the survivors develop serious 86	
neurological disorders [11-14]. C. sakazakii distinct pathovars which are clonal 87	
lineages, of particular clinical significance being clonal complex 4 (CC4) that contains 88	
sequence type 4 (ST4), as well as ST12. These are strongly associated with invasive 89	
meningitis and NEC cases, respectively [15]. One of the most studied NICU 90	
outbreaks was in 1994 when 3 infants died from infections by C. sakazakii ST4 91	
strains  [14].  92	
 93	
For organisms to establish a systemic infection they must adhere to the host cell, 94	
translocate to the underlying tissues, and then disseminate throughout the body. 95	
Therefore, the intestinal epithelium has an important role in protecting the body 96	
against bacterial invasion. Once this layer loses its integrity, the invading organism 97	
can infect the tissue beneath [16]. The ability of C. sakazakii to invade the intestinal 98	
epithelium and brain endothelium is therefore a crucial step for its pathogenesis. It 99	
was shown previously that C. sakazakii has the ability to adhere to epithelial and 100	
endothelial cells in vitro [13, 17]. A study by Townsend et al. [18] used isolates from 101	
the French outbreak in 1994, and showed that the C. sakazakii strains were able to 102	
adhere and invade Caco-2 and rat brain capillary endothelial cells (rBCEC4) cell 103	
lines. Moreover, the organism was able to persist and multiply within the human 104	
macrophage U937 cell line [19]. Another study by Giri et al. [12] showed that food 105	
and environmental strains of C. sakazakii have the ability to invade the HeLa subline 106	
INT407 (human embryonic intestinal cells) and human brain microvascular 107	
endothelial cells (HBMEC).  108	
  109	
The translocation process of the organism follows the initial attachment and invasion 110	
phases. It is the step that initiates the pathogenesis at the next tissue level after 111	
passing through the epithelial layer. Townsend et al. [20] reported that the presence 112	
of lipopolysaccharide (LPS) in infant formula increased the permeability of the 113	
intestinal epithelium leading to the translocation of C. sakazakii. Giri et al. [12] 114	
showed that the invasive food and environmental C. sakazakii strains were able to 115	
translocate intracellularly through the intact monolayers of the Caco-2 and HBMEC 116	
cell lines. This suggests that the bacterium is able to overcome the physical host 117	
barriers in intestines and CNS.  118	
 119	
A number of virulence traits have been identified in Cronobacter, which may facilitate 120	
the invasion and dissemination of the organism in the host. Franco et al. [21] 121	
reported that the plasmid-borne Cronobacter plasminogen activator (Cpa) may 122	
provide resistance to bactericidal activity of serum through cleaving complement 123	
components C3 and C4b, and the activation of plasminogen and inactivation of α2-124	
AP. In a study of over 100 Cronobacter genomes, cpa was found in C. sakazakii and 125	
not C. malonaticus [23; http://pubmlst.org/cronobacter/], and therefore may contribute 126	
to the higher clinical incidence of this species. It has also been reported that the 127	
outer membrane protein A (OmpA) of Cronobacter spp. has a role in the colonisation 128	
of the gastrointestinal tract (GIT) [21, 23]. Also, it was demonstrated that the outer 129	
membrane proteins OmpA and OmpX were required for the basolateral invasion of 130	
enterocyte-like human epithelial cells by C. sakazakii [23]. Singamsetty et al. [24] 131	
demonstrated that the entry of Cronobacter spp. into HBMEC requires ompA 132	
expression and depends on microtubule condensation in these cells. This might help 133	
in the invasion of human intestinal cells and invasion of the brain endothelial cells to 134	
cause meningitis [25]. Moreover, it was recently shown that C. sakazakii ST4 strain 135	
767 was able to produce outer membrane vesicles (OMVs) that have the capacity to 136	
increase the host’s cell prolifration and stimulate a pro-inflammatory innate immune 137	
response [26]. 138	
 139	
This study used clinical isolates of C. sakazakii which had been previously 140	
genotyped by multilocus sequence typing (MLST), and many of which had been 141	
whole genome sequenced [23; http://pubMLST.org/cronobacter/].  The research aim 142	
was to study the virulence potential and pathogenicity of well characterised C. 143	
sakazakii clinical isolates and their ability to overcome host physical barriers and 144	
evade host immune response. 145	
 146	
2. Results 147	
 148	
2.1. Invasion efficiencies of C. sakazakii clinical isolates to Caco-2 and HBMEC cell 149	
lines 150	
 151	
The invasion assay, using gentamicin protection to kill the extracellular bacteria, was 152	
used to assess the ability of 10 C. sakazakii clinical isolates to invade the Caco-2 153	
and HBMEC cell lines. With regard to the Caco-2 cell line, different invasion levels 154	
were noted among these isolates, and strain 695 was the most significant (P<0.05). 155	
The level of invasion by 695 was as high as S. Enteritidis, which was used as 156	
positive control strain for the assay. Strains 20, 767, 1221, and 696 were moderate in 157	
invasion, whereas strains 1240, 1242, 1249, 658 and 680 were low (Fig.1). 158	
Regarding the HBMEC cell line invasion, strain 767 was the most significant (P<0.01) 159	
being as high as Cit. koseri, the positive control. The other strains were moderate 160	
except for strains 658 and 680, which were the lowest (Fig.1). 161	
 162	
 163	
 164	
 165	
Fig.1. C. sakazakii invasion assay using Caco-2 (A) and HBMEC (B) cell lines over 3 166	
hours of incubation showing the differences in invasion levels among strains. The 167	
displayed data are the mean±standard deviation of invasion efficiency % of the initial 168	
inoculum (106 cfu/ml) of two independent experiments in triplicate. The asterisks 169	
above the bars indicate statistically significant differences (*P<0.05; Kruskal-Wallis). 170	
 171	
 172	
 173	
 174	
2.2. Translocation of C. sakazakii clinical through Caco-2 and HBMEC polarised 175	
monolayers 176	
 177	
The aforementioned results showed that C. sakazakii isolates were able to invade 178	
Caco-2 and HBMEC monolayers. Therefore, these isolates were tested for their 179	
ability to translocate through the polarised monolayers of the Caco-2 and HBMEC 180	
cell lines. C. sakazakii strain 695 was the highest in translocating through the Caco-2 181	
cell line over 5 hours of infection (P<0.01). The other strains including 767, 1221, 182	
1240, 1242, 1249, 658, and 696 were moderate, while strains 20 and 680 were the 183	
lowest (Fig.2). With regard to the HBMEC cell line, strains 20, 695, 1221, 1240, and 184	
696 were high in translocation (P<0.01), and strain 767 was the most significant over 185	
5 hours of incubation (P<0.001). C. sakazakii strains 1242 and 1249 were moderate, 186	
whereas 658 and 680 were the lowest (Fig.2). It was noted that the transepithelial 187	
electrical resistance (TEER) declined over the period of the experiment. The higher 188	
drops of TEER were accompanied with high translocation levels (Fig.3), suggesting 189	
that C. sakazakii clinical isolates might translocate through the Caco-2 and HBMEC 190	
cell lines paracellularly.  191	
 192	
 193	
Fig.2. C. sakazakii translocation assay using Caco-2 (A) and HBMEC (B) cell lines 194	
over 5 hours of incubation showing the differences in translocation ability among 195	
strains. The displayed data are the mean±standard deviation of translocation 196	
efficiency % of the initial inoculum (106 cfu/ml) of two independent experiments. The 197	
asterisks above the bars indicate statistically significant differences (*P<0.001, ** 198	
P<0.01; Kruskal-Wallis). 199	
 200	
 201	
 202	
 203	
 204	
Fig.3. Transepithelial electrical resistance (TEER) of the Caco-2 cell line (A) and the 205	
transendothelial electrical resistance (TEER) of the HBMEC cell line (B) over 5 hours 206	
of incubation, showing changes in resistance over time. 207	
 208	
 209	
 210	
 211	
 212	
 213	
 214	
 215	
2.3. C. sakazakii cytotoxic effect on the Caco-2 and HBMEC cell lines 216	
 217	
C. sakazakii clinical strains in this study (n=10) were tested for their cytotoxic impact 218	
using the MTT assay. Apart from strain 680, all the other strains were able to induce 219	
cell death of the Caco-2 cell line, as the assay displayed declined absorbance levels 220	
after 3 hours of incubation indicating low MTT reduction. Although strains 1221, 221	
1240, and 1249 did not follow the same pattern, they however showed lower 222	
absorbance when compared to strain 680. This suggests that these strains, to some 223	
extent, are able to induce cell death more than strain 680 (Fig.4). With regard to the 224	
HBMEC cell line, it did not show susceptibility to cytotoxicity over the first hour of the 225	
assay in contrast to Caco-2 cells; nevertheless after prolonged incubation for 3 hours 226	
the cytotoxic effect appeared to be increased (Fig.4). 227	
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Fig.4. Cytotoxicity of C. sakazakii strains on Caco-2 (A) and HBMEC (B) up to 3 258	
hours of incubation. MTT reduction was used to measure the cytotoxicity levels of C. 259	
sakazakii strains where only the viable HBMEC cells are able to reduce MTT to its 260	
insoluble purple form formazan, the higher absorbance (OD600) the higher in MTT 261	
reduction (low toxicity) and vice versa. The negative control used was uninfected 262	
cells treated using the same protocol with no bacteria added. The data presented in 263	
mean±standard error of mean of three independent experiments. The asterisks 264	
above the bars indicate statistically significant differences between the strains in this 265	
experiment (*P<0.05; ANOVA). 266	
 267	
2.4. C. sakazakii survival within human macrophages U937 268	
 269	
The survival within macrophages is an important indicator of the pathogenicity of the 270	
organism. It enables the persistent bacterium to evade the immune response inside 271	
the host. C. sakazakii clinical isolates were tested for their ability to survive within 272	
human macrophages using U937 cell line. All strains were taken up by these cells 273	
and showed persistence for up to 72 hours (Fig.5). However, strain 680 declined 274	
significantly after 72 hours. The other strains demonstrated different levels of 275	
multiplication at 24 hours and strains 20, 695, 767, 1221, 658, and 696 were the 276	
most significant (P<0.05). 277	
 278	
2.5. C. sakazakii survival within human microglial cells 279	
 280	
Microglial cells are brain resident macrophages, which respond rapidly to the 281	
presence of the pathogens and brain damage. Furthermore, they perform 282	
phagocytosis, antigen presentation, and are responsible for cytokine secretion. 283	
Microglial cells are able to migrate to the injured brain tissues to remove the 284	
damaged ones [27]. C. sakazakii is linked to fatal meningitis cases, and therefore it is 285	
important to consider its ability to resist phagocytosis and withstand killing inside the 286	
brain. This experiment was conducted to assess the ability of C. sakazakii to survive 287	
within microglial cells and multiply intracellularly. C. sakazakii clinical strains were 288	
able to survive up to 72 hours post infection (Fig.5). However, strains 695, 1242, 658, 289	
and 696 showed lower survival levels. Additionally, strain 680 was taken up and 290	
killed rapidly following the uptake. Strains 20, 767, 1221, 1240, and 1249 multiplied 291	
significantly at 24 hours (P<0.001).	292	
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Fig.5. C. sakazakii uptake and persistence assay using human macrophage (A) and 346	
human microglia (B) cell lines over 72 hours of incubation showing the differences in 347	
survival among strains. The displayed data are the mean±SEM for uptake and 348	
persistence efficiency % of the initial inoculum (105 cfu/ml) of three independent 349	
experiments. The asterisks above the bars indicate statistically significant differences 350	
(*P<0.05, **P<0.001; ANOVA). 351	
 352	
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2.6. C. sakazakii resistance to human serum 357	
	358	
All C. sakazakii strains in this experiment (n=10) showed up to 60% decrease in their 359	
viable count at the first hour incubation with human serum (Fig.6). After the second 360	
hour of incubation, it was noted that 9/10 strains showed an increase in their viable 361	
numbers, whereas strain 680 showed a 30% reduction in its viability. The majority of 362	
the strains were able to survive in human serum and increased by up to 4-fold in their 363	
numbers after 3 hours of incubation. The exception was strain 680, which was serum 364	
sensitive and its growth declined dramatically to 60% (P<0.05). Strains 20, 1242, 365	
1249, and 696 were the highest in serum tolerance showing considerable elevated 366	
growth rates (>200%) during the period of the assay. 367	
 368	
Franco et al. [21] reported that the outer membrane protease Cpa of Cronobacter is 369	
responsible for serum resistance. All C. sakazakii clinical strains in this research 370	
were tested for the presence of the cpa gene using PCR probing and BLAST search. 371	
Most (9/10) of the strains were confirmed positive for this gene. These strains 372	
demonstrated resistance to human serum except for strain 680, which lacked the 373	
presence of cpa gene in PCR and BLAST search and was serum sensitive. It was 374	
shown that strain 680 lack the presence of pESA3 plasmid, but on the other hand a 375	
pESA3-like plasmid was present in this strain, which lacked some plasmid-borne 376	
virulence genes [22]. 377	
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Fig.6. Sensitivity of C. sakazakii to human serum over 3 hours of incubation showing 397	
the difference in growth among strains overtime. Most of the strains showed 398	
increases in their viable counts, and strains 6 (ST4), 680 (ST4), and E. coli K12 399	
showed significantly declined values. The displayed data are the mean±standard 400	
deviation of survival % (106 cfu/ml initial inoculum) of two independent experiments. 401	
The asterisks above the bars indicate statistically significant differences (*P<0.05; 402	
Kruskal-Wallis). 403	
 404	
3. Discussion 405	
 406	
This study used a range of clinical isolates of C. sakazakii. These strains were 407	
diverse with respect to their temporal and geographical sources, and all but one 408	
strain were from patients with clinical presentations. The exception was C. sakazakii 409	
658 (ATCC BAA-894) which had been isolated from the formula, that was not 410	
intended for infants, used in the fatal NICU C. sakazakii outbreak at the University 411	
of Tennessee [7]. The corresponding CSF isolate has not been deposited in any 412	
international culture collection and therefore the PFGE indistinguishable strain 413	
(ATCC code BAA-894) was used instead. This was also the first genome-sequenced 414	
strain of Cronobacter, including the pESA3 plasmid which encodes for the cpa gene 415	
[2]. 416	
 417	
Tissue culture assays were applied to examine the bacterial-host interaction and to 418	
assess the ability of C. sakazakii strains to overcome human intestinal and brain 419	
barriers represented by the Caco-2 and HBMEC cell lines. All the strains were able 420	
to invade the Caco-2 cell line (Fig.1). However, there was strain to strain variation in 421	
the level of invasion, with strain 695 (ST4) being the most invasive and was similar to 422	
that of the positive control S. Enteritidis strain (P<0.05). With reference to HBMEC 423	
cell line invasion, most of the strains showed moderate invasion levels and strain 767 424	
(ST4) displayed significant high invasion level (P<0.01). Whereas, strains 658 (ST1) 425	
and 680 (ST8) showed the lowest invasion (Fig.1).  426	
 427	
Overall, the invasion results indicated that the majority (9/10) of the strains were able 428	
to invade the cell lines and therefore potentially translocate towards the underlying 429	
tissues and blood stream. Consequently, this could lead to the dissemination of the 430	
organism around the body. To further investigate the translocation process further, 431	
assays using the same human cell lines were applied. All strains were able to 432	
translocate through the Caco-2 cell line especially strain 695 that displayed 433	
significant high translocation ability (P<0.01), while strain 696 (ST12) was moderate 434	
(Fig.2). These strains were able to cause high cytotoxicity levels to the Caco-2 cell 435	
line, which could lead to increase the cell line permeability causing more bacterial 436	
translocation (Fig.4). Strain 695 (ST4) accounted for a fatal neonatal NEC infection 437	
while strain 696 (ST12) was previously linked to neonatal NECII infection [14]. The 438	
invasion and translocation results correlate their virulence and their ability to cause 439	
that disease.  440	
 441	
There was a significant decrease in TEER when using the invasive and translocating 442	
strains indicating a disruption in the tight junctions (Fig.3). This might explain the 443	
mechanism of translocation for the strains where they can migrate in between the 444	
cells by altering the tight junctions. This might trigger the onset of NEC, which could 445	
lead to the spread of the bacteria in the blood stream. This clinical presentation of the 446	
organism indicates the potential to reach the brain microvascular endothelium and 447	
invades its cells. Therefore the translocation assay using the HBMEC cell line was 448	
initiated to investigate whether the organism has the ability to translocate through 449	
these cells or not. ST4 strains 20, 695, 1221, and 1240 in addition to 696 (ST12) 450	
were high in translocation (P<0.01), and strain 767 (ST4) was the most significant in 451	
translocation over 5 hours of incubation (P<0.001; Fig.2). C. sakazakii strains 1242 452	
(ST4) and 1249 (ST31) were moderate in translocation, whereas 658 (ST1) and 680 453	
(ST8) were the lowest. Strains 695 (ST4), 767 (ST4), and 696 (ST12), which showed 454	
high translocation rates were the highly cytotoxic strains to the HBMEC cell line 455	
(Fig.4). Strain 767 (ST4) that exhibited the most significant translocation through 456	
HBMEC cell line was associated with a fatal meningitis case [14] and also produces 457	
cytopathogenic OMVs [26]. Overall, the HBMEC TEER was stable during the first 4 458	
hours of incubation, indicating the stability of the tight junctions and the integrity of 459	
the cell line. However, after 5 hours of infection it displayed declined levels with the 460	
translocated strains (Fig.3). The decrease in TEER might be attributed to the 461	
deterioration of endothelial integrity that could be accredited to the cytotoxic killing to 462	
the HBMEC cell line that was caused by those strains.  463	
 464	
The translocated strains might need a longer infection period to accomplish the 465	
translocation process, as the translocation was noted 5 hours post infection, while in 466	
Caco-2 it was after 1 hour with some strains. Moreover, they could use different 467	
mechanisms of invasion to overcome this barrier that is a part of the BBB. One of the 468	
possible mechanisms that might assist the strains to translocate is the bacterial 469	
cytotoxicity that leads to initiate cell death in the cell line via apoptosis or necrosis. 470	
Moreover, the cytokines released by the cells might play a role in the same process 471	
by making the cell line permeable. High levels of nitric oxide (NO) are a potential 472	
factor that could contribute in the permeability of the cell line. Also, OMVs might 473	
contribute in this process by triggering the host proinflammatory response leading to 474	
the secretion of some inflammatory mediators, including cytokines and NO, that in 475	
turn could cause cell line permeability [26]. The translocation of these strains 476	
indicated their potential to pass through towards the brain tissues triggering the host 477	
response, which could result in brain inflammation and tissue damage. 478	
 479	
In a previously published study by Giri et al. [12], non-clinical C. sakazakii isolates 480	
were examined and showed their ability to invade and translocate through the Caco-481	
2 and HBMEC cell lines intracellularly. In this research, the same cell lines were used 482	
to compare the results of the clinical strains in our study and the non-clinical strains 483	
from the previous research by Giri et al. [12] with regard to the capacity and 484	
mechanism of translocation. However, the resultsWe found that of the capacity of 485	
translocationtranslocation ability of C. sakazakii clinical isolates that were obtained 486	
by our research were was more than 10 times higher than the previous study using 487	
the same cell lines. Additionally, our results showed suggested a different 488	
mechanism of translocation, which istheir capacity of paracellular translocation 489	
through those cell lines. All of the strains were from clinical sources and were linked 490	
to severe and fatal neonatal cases.  491	
 492	
The survival studies were conducted to investigate the ability of the test strains to 493	
survive and multiply within macrophages and microglia which are both types of 494	
immune cells. C. sakazakii strains used in the survival experiments showed the 495	
ability to persist within human macrophages cell line U937 for up to 72 hours of 496	
incubation. Moreover, ST4 strains 20, 767, and 1221 in addition to 658 (ST1) were 497	
able to survive and multiply significantly (P<0.001). The survival results were 498	
comparable to the results obtained previously by Townsend et al. [18]. Strains 767 499	
(ST4) and 696 (ST12) showed similar persistence and multiplication levels as the 500	
ones published in that research. However, Townsend et al. [18] reported that strain 501	
695 (ST4) was able to survive and could not multiply within macrophages. These 502	
results are in contrast of the ones obtained here as strain 695 (ST4) showed the 503	
ability to survive and multiply in U937 cells. Our results correlate the virulence 504	
potential of the strain, and the invasion and translocation profiles, as it was an 505	
invasive strain to both of the Caco-2 and HBMEC cell lines. Moreover, it is a clinical 506	
strain that was linked to a fatal NEC infection [14]. This suggests that this strain was 507	
able to establish a successful infection and has the virulence traits to avoid 508	
phagocytic killing.  509	
 510	
The survival and multiplication within macrophages could help the organism to use 511	
macrophages as a vehicle to invade the other body organs. This mechanism is called 512	
the “Trojan horse” and where the organism translocates through tissues inside 513	
macrophages. This mechanism allows the bacterium to hide inside the phagocytic 514	
cells, escape from the immune response, and reach the other body organs such as 515	
the brain [28]. Some cytokines secreted by the infected tissues, such as IL-8, attract 516	
phagocytic cells and make these tissues permeable and leaky allowing the immune 517	
cells to migrate to the site of infection, and help in increasing the number of the 518	
invading organism [29-31]. The damage could be indicated by the host response 519	
induced by the bacterium. Moreover, the persistent strains were confirmed to be 520	
serum resistant, and these two characteristics enhanced their ability to avoid the host 521	
immune response and cause bacteraemia, which could be advantageous for the 522	
organism to migrate through the BBB endothelium. 523	
 524	
Microglia are brain resident innate immune cells that are responsible for 525	
phagocytosis as well as the ability to produce inflammatory mediators such as NO 526	
and TNF-α [27, 32, 33]. Although their ability to eliminate C. sakazakii CNS infection 527	
in vitro has not yet been examined, we are the first to report the ability of C. sakazakii 528	
to survive within human microglial cells. It was shown in this research that the 529	
majority of C. sakazakii strains were able to persist in human microglia as 530	
represented by the HMGC cell line for 72 hours. Moreover, ST4 strains 20, 767, 531	
1221, and 1240 in addition to 1249 multiplied significantly in this cell line (P<0.001). 532	
Although these strains showed the ability to multiply within microglia, they 533	
nevertheless showed declined levels of persistence afterwards. The ability of the 534	
bacteria to reproduce intracellularly within these phagocytic cells demonstrates their 535	
virulence potential to withstand the bactericidal activity of microglia and evade the 536	
host immune response. 537	
 538	
Invasive microorganisms have protective mechanisms against serum-mediated 539	
killing. Bacterial structures including outer membrane proteins and proteases were 540	
identified for their roles to avoid this bactericidal action [34-36]. Franco et al. [21] 541	
showed that the Cpa is a plasminogen activator that plays an essential role in 542	
Cronobacter serum resistance. Nine of the ten C. sakazakii strains in this research 543	
were regarded as serum resistant being able to replicate in human serum and 544	
appeared to be completely refractory to serum killing. Whereas C. sakazakii strain 545	
680 was serum sensitive and showed significant reduction in viability (P<0.05; Fig 6). 546	
 547	
Franco et al. [21] further showed that a cpa mutant of C. sakazakii BAA-894 548	
(synonym for 658 in this study) was serum sensitive compared with the wild type. In 549	
our study 9/10 C. sakazakii strains were serum resistant and also encoded for the 550	
cpa gene. The exception being strain 680 which lacked this gene and was serum 551	
sensitive. While strain 680 was the only ST8 strain studied here, a BLAST search of 552	
the PubMLST database revealed the cpa gene is absent from all (n=8) genome 553	
sequenced ST8 strains. This absence could explain the observation by Forsythe et 554	
al. [15] in a review of >1000 Cronobacter strains, that C. sakazakii ST8 is not 555	
associated with severe Cronobacter infections [8]. By inference therefore, cpa could 556	
be an important factor in C. sakazakii resistance to serum killing in the host and 557	
enabling dissemination around the neonate’s body.  558	
	559	
In conclusion, C. sakazakii clinical isolates showed the ability to invade and 560	
translocate through Caco-2 and HBMEC cell lines. Moreover, they demonstrated the 561	
ability to persist and multiply within macrophages and microglial cells. Additionally, 562	
the isolates were resistant to human serum bactericidal effect. However, it was noted 563	
that strain 680 did not follow the same pattern of virulence and pathogenicity as it 564	
was low in invasion, translocation, and phagocytosis survival in addition to being 565	
sensitive for human serum killing. This might be attributed to lack of the pESA3 566	
plasmid [22], and hence other plasmid-borne virulence genes such as cpa, and other 567	
genes involved in invasion, translocation, and phagocytosis survival . Although this 568	
strain was a CSF isolate it demonstrated a weakness in pathogenicity to HBMEC and 569	
microglial cells in vitro. It was reported that C. sakazakii ST12 has been associated 570	
with cases of necrotizing enterocolitis [15]. It was shown in this study that strain 696 571	
(ST12) was able to invade and translocate through the Caco-2 cell line in addition to 572	
its ability to induce cytotoxicity to the same cell line. This might indicate its ability to 573	
induce necrotizing enterocolitis in vivo. Furthermore, it was observed that the most 574	
invasive and translocated strains in this research were in the C. sakazakii ST4 clonal 575	
complex, which is the lineage that linked to the most neonatal meningitis cases 576	
worldwide [37]; Table 1.	ST4 strains such as 695, 767, 1221, 1240, and 1242 within 577	
clonal complex 4 were invasive and highly translocated isolates and were 578	
responsible for fatal NEC and meningitis infections. This indicates their ability to 579	
translocate through the gut mucosa and BBB in vivo and cause NEC and meningitis. 580	
It is important to further study the strains among this clonal complex and discover 581	
their pathogenicity traits and their role in triggering the host response and its 582	
outcome.  583	
 584	
4. Materials and methods 585	
 586	
4.1. Bacterial strains 587	
 588	
Ten C. sakazakii strains were used in this research (Table.1). These isolates were 589	
from Nottingham Trent University culture collection. Additional metadata for all 590	
strains can be obtained from the open access Cronobacter PubMLST database: 591	
www.pubmlst.org/cronobacter/. The strains were chosen according to their source 592	
and clinical outcomes, and well-characterised strains from the 1994 French outbreak 593	
and University of Tennessee [7, 14]. For routine culturing the strains were grown on 594	
TSA (Oxoid, UK) under aerobic conditions at 37°C for overnight.  595	
 596	
 597	
 598	
 599	
 600	
 601	
 602	
 603	
 604	
 605	
Table.1 606	
Cronobacter sakazakii strains used in this study 607	
 608	
Strain 
Sequence 
type (clonal 
complex) 
Source Clinical presentation Country 
20 4 (CC4) Clinical Unknown Czech Republic 
695 4 (CC4) Clinical - Trachea Fatal NEC II France 
767 4 (CC4) Clinical - Trachea Fatal meningitis France 
1221 4 (CC4) Clinical - CSF Meningitis USA 
1240 4 (CC4) Clinical - CSF Fatal meningitis USA 
1242 4 (CC4) Clinical - Brain Fatal meningitis USA 
1249 31 (CC31) Clinical Fatal infant isolate UK 
658a 1 (CC1) NIFNIF Meningitis USA 
680 8 (CC8) Clinical - CSF Unknown USA 
696 12 Clinical - Faeces NEC II France 
NEC: Necrotising enterocolitis. CSF: Cerebrospinal fluid. CC: clonal complex. NIF: Non-infant formula.  609	
a Also known as C. sakazakii BAA-894. 610	
 611	
4.2. Cell culture 612	
 613	
Human colonic carcinoma epithelial cells (Caco-2) passages 17 to 45 acquired from 614	
the European Collection of Cell Cultures (ECACC #86010202) and human brain 615	
microvascular endothelial cells passages 2 to 25 (HBMEC; ref. #HMG030 Inooprot, 616	
Spain). Macrophage cell line (U937) passage 12 was obtained from American Type 617	
Culture Collection (ATCC; #CRL-1593.2), and human microglial cell line passage 3 618	
was obtained from Innoprot Technologies (Ref.# P10354). All experiments were 619	
applied at consistent conditions of time, temperature, cell line passage, mammalian 620	
cells concentration, and bacterial suspension. Salmonella Enteritidis strain NTU 358 621	
was used as positive control for Caco-2 cell line, while Citrobacter koseri strain NTU 622	
48 was the positive control for HBMEC, macrophages, and microglial cell lines. 623	
Escherichia coli K12 strain NTU 1230 was the negative control for all cell lines. 624	
 625	
4.3. Bacterial invasion of mammalian cells 626	
 627	
This experiment was as described previously by Townsend et al. [18] with slight 628	
modifications. Caco-2 cells were grown in Minimum Essential Medium (MEM) 629	
supplied with 10% (v/v) foetal calf serum (FCS), 1% (v/v) non-essential amino acid 630	
(NEAA), and 1% (v:v)  penicillin-streptomycin (Sigma Aldrich, UK). HBMEC were 631	
grown in Dulbecco’s modified eagle medium (DMEM) with 10% (v/v) FCS and 1% 632	
(v/v) penicillin-streptomycin (Sigma Aldrich, UK).	Mammalian cells then were seeded 633	
at 4x104 cell/well in growth medium for 48 hours in 5% CO2 at 37°C to achieve a 634	
confluent monolayer. C. sakazakii strains were grown in LB broth for overnight at 635	
37°C. The suspension then was added to the wells at MOI 100, and incubated in 5% 636	
CO2 at 37°C for 2 hours. The wells were then washed using PBS (Sigma Aldrich, 637	
UK). Then, 0.5 ml of infection medium supplied with 125 μg/ml (v/v) of gentamicin 638	
(Sigma Aldrich, UK) was added and incubated in 5% CO2 at 37°C for 1 additional 639	
hour. The wells were then washed with PBS (Sigma Aldrich, UK) before lysing by 1% 640	
(v/v) Triton X-100 (Fisher Scientific, UK), and plated on TSA at 37°C for overnight 641	
incubation after serial dilution to obtain viable count. Data are presented as the 642	
percentage efficiency of invasion. 643	
	644	
4.4. Translocation assay using Caco-2 cell line 645	
 646	
Translocation assay was performed as previously described [12, 38]. However, 0.8 647	
ml of growth medium was added to the basolateral chamber of Millicell-24 cell culture 648	
plate (Millipore, UK). Caco-2 cells, at a concentration of 4x104 cell/well in 0.4 ml/well 649	
of Minimum Essential Medium (MEM) supplied with 10% (v/v) foetal calf serum 650	
(FCS), 1% (v/v) non-essential amino acid (NEAA), and 1% (v/v) penicillin-651	
streptomycin (Sigma Aldrich, UK), were seeded onto a 3 μm pore polycarbonate 652	
transwell membrane in the apical chamber of the tissue culture plate and incubated 653	
in 5% CO2 at 37°C. The medium in the apical and the basolateral chambers was 654	
changed every 3 days. Millicell ERS-2 Volt-Ohm Meter (Millipore, UK) was used to 655	
measure the TEER. The Caco-2 cell line required up to 21 days to form intact 656	
polarised monolayers with TEER 300-850 Ωcm-2 [12, 38, 39]. On the day of the 657	
assay, the medium in the basolateral chamber was replaced with infection medium. 658	
The medium in the apical chamber was removed, and the membrane was washed 659	
using 0.4 ml of PBS (Sigma Aldrich, UK). Bacterial suspensions was prepared was 660	
added at MOI 100 to the apical chamber. At each time point of incubation, the 661	
basolateral chamber was sampled for viable count after serial dilution and inoculation 662	
on TSA. The TEER was measured at each time point. Data are presented as the 663	
percentage efficiency of translocation. 664	
 665	
4.5. Translocation assay using HBMEC cell line 666	
 667	
This assay was carried out using the protocol described previously [12, 40, 41]. The 668	
basolateral chambers of the 24-well plate were filled with 0.510 ml/well of Dulbecco’s 669	
modified eagle medium (DMEM) with 10% (v/v) FCS and 1% (v/v) penicillin-670	
streptomycin (Sigma Aldrich, UK). Cells, with a concentration of 4x104 cell/well in 671	
0.375 ml/well of previous medium, were seeded onto the apical part of collagen-672	
coated polytetrafluoroethylene (PTFE) membrane with a pore size of 0.4 μm 673	
(Transwell-COL; Corning, USA), and incubated in 5% CO2 at 37°C. The medium in 674	
the apical chamber was changed every 3 days. The transendothelial electrical 675	
resistance (TEER) was measured using Millicell ERS-2 Volt-Ohm Meter (Millipore, 676	
UK). According to electrical resistance measurements, HBMEC cell line required 5 to 677	
8 days to form intact polarised monolayers with TEER 300-600 Ωcm-2 [12, 42]. Prior 678	
to infecting the cell line, the filter was washed by 0.375 ml/well PBS (Sigma Aldrich, 679	
UK), and the medium in the basolateral part was replaced by infection medium. The 680	
cell line was infected by 0.375 ml per well bacterial suspension with MOI of 100. The 681	
basolateral chamber was sampled and serially diluted and then plated for viable 682	
count on TSA at 37°C before replacing with a fresh infection medium. Moreover, the 683	
TEER of the monolayers was measured at each time point. Data are presented as 684	
the percentage efficiency of translocation. 685	
	686	
4.6. C. sakazakii cytotoxic effect on the Caco-2 and HBMEC cell lines 687	
 688	
The ability of C. sakazakii to induce cytotoxicity was assessed using the colorimetric 689	
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide) assay.	This assay 690	
is based on the reduction of MTT (Sigma Aldrich, UK) by viable cells to its insoluble 691	
form formazan, which has a purple colour. This experiment was applied as described 692	
previously [43, 44]. Briefly, bacterial suspensions at a concentration of 4x106 cfu/well 693	
(MOI 100) were added to confluent monolayers of the Caco-2 and HBMEC cell lines. 694	
The plates were then incubated in 5% CO2 at 37°C for 1 and 3 hours. A volume of 50 695	
μl of MTT was added per 500 μl of culture medium. Next, the medium containing 696	
MTT was removed and formazan was solubilised in dimethyl sulfoxide (DMSO; 697	
Fisher Scientific, UK). The absorbance was measured at 600nm after 3 hours. The 698	
negative control for the assay consisted of uninfected cells. 699	
 700	
4.7. C. sakazakii persistence in human macrophages 701	
 702	
As previously given by Townsend et al. [19] with slight modifications, macrophages 703	
were grown in RPI medium containing 10% (v/v) FCS, 1% (v/v) NEAA, and 1% (v/v) 704	
penicillin-streptomycin (Sigma Aldrich, UK),	 and then treated with growth medium 705	
contains 2 mM L-glutamine, 10 mM HEPES, and 1 mM sodium pyruvate (Sigma 706	
Aldrich, UK) for maturation. Before seeding the 24-well plates, phorbol 12-myristate 707	
13-acetate (PMA; Sigma Aldrich, UK) at a concentration of 0.1 μg/ml (v/v) was added 708	
for promoting cell adhesion. The cells were then plated into 24-well plates at a 709	
concentration of 4x104 cell/well and incubated in 5% CO2 at 37°C for 72 hours to get 710	
confluent monolayer. Macrophages were infected by overnight-cultured bacterial 711	
suspensions with MOI 10. The plates then were incubated 1 hour in 5% CO2 at 37°C. 712	
After the previous incubation period, the medium was aspirated and replaced with 713	
infection medium containing 125 μg/ml (v/v) of gentamicin and incubated in 5% CO2 714	
at 37°C for 1 hour. Four plates were then washed by PBS and supplied with infection 715	
medium contains 50 μg/ml (v/v) of gentamicin for further incubation. After each time 716	
point of incubation, the plates were washed by PBS before lysing by 1% (v/v) Triton 717	
X-100, and then serially diluted before plating on TSA to obtain the intracellular 718	
bacteria at different time points. Data are displayed in percentage of uptake and 719	
persistence. 720	
 721	
4.8. C. sakazakii persistence in human microglial cells 722	
 723	
As previously described by Liu et al. [45] with slight modifications, microglial cells 724	
were grown in basal medium containing 10% (v/v) FCS, 10% (v/v) microglial growth 725	
supplement, and 1% (v/v) penicillin-streptomycin (Innoprot, Spain) for three days in 726	
75 cm3 tissue culture flask. The cells then were seeded into four 24-well plates at a 727	
concentration of 4x104 cell/well and incubated in 5% CO2 at 37°C for 48 hours to 728	
achieve confluency. Next, the cells were infected by overnight-cultured bacteria with 729	
MOI 10. Afterwards, the plates were incubated for 1 hour in 5% CO2 at 37°C. The 730	
medium then was aspirated and replaced by infection medium contains 125 μg/ml 731	
(v/v) of gentamicin and incubated in 5% CO2 at 37°C for 1 hour after washing by 732	
PBS. Three plates were then washed 3 times by PBS and supplied with infection 733	
medium contains 50 μg/ml (v/v) of gentamicin for further incubation. At the end of 734	
each time point of incubation, the cells were washed by PBS before lysing with 1% 735	
(v/v) Triton X-100, and plated on TSA after being serially diluted to obtain the 736	
intracellular bacteria at different time points. Data are displayed in percentage of 737	
uptake and persistence. 738	
 739	
4.9. C. sakazakii sensitivity to human serum 740	
 741	
The sensitivity of C. sakazakii strains to active human serum was conducted as 742	
described previously by Hughes et al. [46] with slight modification. Bacterial cultures 743	
were grown overnight in LB at 37°C with shaking at 200 rpm then centrifuged for 10 744	
minutes at 1300 rpm (Mikro 200-Hettik). The pellet then was re-suspended to 106 745	
cfu/ml in 5 ml of phosphate buffered saline (PBS; Sigma Aldrich, UK). A volume of 746	
0.5 ml of the suspension was added into 1.5 ml of undiluted active human serum 747	
(Sigma Aldrich, UK). The samples were loaded into a 24-well plate and incubated at 748	
37°C. Viable counts were obtained at 4 different time points. Data are displayed in 749	
percentage of percent survival of inoculum. 750	
 751	
4.10. PCR probing for cpa gene and BLAST genome search 752	
 753	
Plasmid DNA extraction was carried out according to the manufacturer’s instructions 754	
using QIAprep Spin Miniprep Kit (Qiagen, UK). PCR primers were designed to target 755	
cpa loci on the large C. sakazakii plasmid pESA3 plasmid. GoTaq® DNA Polymerase 756	
kit (Promega, UK) was used for all PCR reactions’ preparation. Primers design, and 757	
the PCRs were all conducted according to Franco et al. [25]. All reactions started 758	
with 3 minutes at 94°C and denaturation step at 94°C for 30 seconds, followed by 25 759	
cycles of 30 s at 56 °C and 30 s at 72 °C. The final extension period was 10 min at 760	
72 °C. Primer pair cpafw, 5’-GACAACCCTGAGTTCTGGTAAC, and cparv, 5’-761	
ATGCGTATTTCTGCTGGTAA, targets a 306 bp region. Moreover, BLAST genome 762	
search was applied to strains using the sequence of cpa gene to confirm its 763	
presence. The BLAST search was at http://www.pubmlst.org/cronobacter.  764	
 765	
4.11. Statistical analysis 766	
 767	
Data were assessed for normality using Kolmogorov-Smirnov test and normality 768	
histograms. The normally distributed data were analysed using the parametric One-769	
way Analysis of Variance test (ANOVA) with Tukey’s post-hoc test, and were 770	
expressed as mean values and the standard error of mean (Mean±SEM). Data that 771	
were not normally distributed were subjected to Kruskal-Wallis test, the non-772	
parametric equivalent of the parametric ANOVA, and were expressed as mean 773	
values and the standard deviation (Mean±SD). Tukey’s post-hoc analysis was 774	
performed as a single step multi-comparison test to compare the significance of the 775	
means of every C. sakazakii strain in relation to other strains as pairwise 776	
comparisons. A P-value of <0.05 was considered statistically significant. Computer 777	
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statistical analysis software was used to perform the analysis (IBM SPSS version 778	
22.0, Chicago, IL, USA). 779	
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